Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABANASDAQ:EOLSNASDAQ:IMNMNASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$1.56+2.3%$1.68$0.99▼$8.77$79.41M2.811.65 million shs1.17 million shsEOLSEvolus$9.52+3.4%$10.13$8.67▼$17.82$613.59M1746,604 shs257,880 shsIMNMImmunome$8.80-5.4%$8.64$5.15▼$16.81$762.64M1.94884,425 shs459,547 shsPRAXPraxis Precision Medicines$43.01+2.3%$39.90$26.70▼$91.83$875.71M2.61365,889 shs50,250 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio-3.18%-13.14%-18.72%+29.91%-79.68%EOLSEvolus+0.77%-1.81%-1.71%-23.19%-15.12%IMNMImmunome+6.04%+6.41%+4.97%+48.56%-23.14%PRAXPraxis Precision Medicines-2.21%+1.01%+8.99%+17.23%+1.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCABACabaletta Bio2.2844 of 5 stars3.52.00.00.02.70.80.6EOLSEvolus4.0435 of 5 stars3.50.00.03.53.33.30.6IMNMImmunome2.2324 of 5 stars3.52.00.00.02.22.50.0PRAXPraxis Precision Medicines3.2267 of 5 stars4.42.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 3.00Buy$14.43827.88% UpsideEOLSEvolus 3.00Buy$23.75149.47% UpsideIMNMImmunome 3.00Buy$23.33165.15% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$92.11114.16% UpsideCurrent Analyst Ratings BreakdownLatest CABA, PRAX, EOLS, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/11/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.005/15/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/AEOLSEvolus$266.27M2.31N/AN/A$0.09 per share105.78IMNMImmunome$9.04M84.70N/AN/A$2.27 per share3.88PRAXPraxis Precision Medicines$8.55M102.47N/AN/A$23.90 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)EOLSEvolus-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)IMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)Latest CABA, PRAX, EOLS, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A3.963.96EOLSEvolus22.002.342.16IMNMImmunomeN/A10.4910.49PRAXPraxis Precision MedicinesN/A8.448.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/AEOLSEvolus90.69%IMNMImmunome44.58%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%EOLSEvolus6.10%IMNMImmunome8.60%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio5050.74 million45.03 millionOptionableEOLSEvolus17064.48 million60.54 millionOptionableIMNMImmunome4087.01 million79.53 millionOptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionableCABA, PRAX, EOLS, and IMNM HeadlinesRecent News About These CompaniesPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesJune 28 at 2:35 AM | marketbeat.comAssenagon Asset Management S.A. Sells 51,682 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)June 14, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)June 12, 2025 | marketbeat.comBank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)June 12, 2025 | marketbeat.comFormer head trader of Denver-based investing company pleads guilty to insider tradingJune 9, 2025 | finance.yahoo.comWeston man pleads guilty to insider trading offense that made him $220KJune 8, 2025 | stamfordadvocate.comSPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's WhyJune 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLPJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLCJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at OppenheimerJune 2, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial MarketsJune 1, 2025 | marketbeat.comPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationMay 7, 2025 | msn.comPraxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor EventMay 5, 2025 | finance.yahoo.comPraxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)May 4, 2025 | finance.yahoo.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comPraxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | BenzingaApril 21, 2025 | benzinga.comPraxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, PRAX, EOLS, and IMNM Company DescriptionsCabaletta Bio NASDAQ:CABA$1.56 +0.04 (+2.30%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Evolus NASDAQ:EOLS$9.52 +0.31 (+3.37%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Immunome NASDAQ:IMNM$8.80 -0.50 (-5.38%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Praxis Precision Medicines NASDAQ:PRAX$43.01 +0.96 (+2.28%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
